A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
Status:
Terminated
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients
will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the
treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC
1295 or placebo.
The objective is to assess and compare the efficacy, pharmacokinetics, safety, and
tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated
visceral obesity.